Regentatlantic Capital LLC Novo Cure LTD Transaction History

Regentatlantic Capital LLC

$3.34 Billion
Q3 2022

A detailed history of Regentatlantic Capital LLC transactions in Novo Cure LTD stock. As of the latest transaction made, Regentatlantic Capital LLC holds 3,015 shares of NVCR stock, worth $92,862. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,015

Previous 3,015 -0.0%

Holding current value

$92,862

Previous $210,000 9.05%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$116.17 - $194.55 $348 - $583	-3 Reduced 0.1%	3,015 $350,000
Q1 2021 Apr 29, 2021	SELL	$124.11 - $190.17 $19,485 - $29,856	-157 Reduced 4.94%	3,018 $399,000
Q4 2020 Feb 04, 2021	SELL	$112.16 - $174.14 $116,646 - $181,105	-1,040 Reduced 24.67%	3,175 $549,000
Q3 2020 Oct 13, 2020	BUY	$58.05 - $111.31 $5,108 - $9,795	88 Added 2.13%	4,215 $469,000
Q2 2020 Aug 13, 2020	BUY	$57.2 - $74.41 $858 - $1,116	15 Added 0.36%	4,127 $245,000
Q1 2020 May 14, 2020	SELL	$57.05 - $95.75 $50,660 - $85,026	-888 Reduced 17.76%	4,112 $277,000
Q2 2019 Jul 23, 2019	SELL	$42.22 - $63.23 $4,728 - $7,081	-112 Reduced 2.19%	5,000 $316,000
Q1 2019 May 03, 2019	SELL	$31.96 - $56.12 $66,125 - $116,112	-2,069 Reduced 28.81%	5,112 $246,000
Q4 2018 Jan 30, 2019	BUY	$28.72 - $52.63 $3,216 - $5,894	112 Added 1.58%	7,181 $240,000
Q2 2018 Jul 31, 2018	BUY	$19.85 - $32.0 $140,319 - $226,208	7,069 New	7,069 $221,000
Q1 2018 Apr 23, 2018	SELL	$19.3 - $23.65 $372,374 - $456,303	-19,294 Closed	0 $0
Q3 2017 Oct 25, 2017	BUY	$18.05 - $21.75 $348,256 - $419,644	19,294	19,294 $383,000

Others Institutions Holding NVCR

# of Institutions

263

Shares Held

77M

Call Options Held

1.17M

Put Options Held

318K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.23B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Regentatlantic Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Regentatlantic Capital LLC with notifications on news.

Account

Regentatlantic Capital LLC Novo Cure LTD Transaction History